NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

July 1, 2022

Conditions

Colorectal CancerRAS and BRAF Wild-typeColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Interventions

DRUG

Anlotinib Hydrochloride

Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.

DRUG

Capecitabine

Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2,D1

Trial Locations (2)

310000

The Second Affiliated Hospital of Zhejiang University, Hangzhou

Unknown

Zhejiang Cancer Hospital, Hangzhou